Intrexon | XON - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agenus USD 34.2M 4.61M 2025-12
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Amgen USD 6.89B 415M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.61B 225M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Intrexon USD -297K 167K 2024-06
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Veracyte USD 101.97M 10.69M 2025-12
Xencor USD 21M 22.61M 2025-09